Want to see HK:2171 full AI Analyst Report?
2171 Stock Chart & Stats
HK$14.89
HK$0.27(2.96%)
At close: 4:00 PM EST
HK$14.89
HK$0.27(2.96%)
Day’s Range― - ―
52-Week RangeHK$10.87 - HK$28.60
Previous CloseN/A
Volume4.65M
Average Volume (3M)1.98M
Market Cap
HK$8.59B
Enterprise ValueHK$6.59B
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$61.20M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 25, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding602,494,000
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)9.40
Price to Sales (P/S)58.60
P/FCF Ratio-30.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.70Price Target Upside72.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)HK$433.36M
Bulls Say, Bears Say
Bulls Say
Revenue Momentum And Positive Gross ProfitSustained top-line growth and a return to positive gross profit signal improving product or service traction and better unit economics. This trend de-risks the path toward operating leverage and eventual profitability if revenue scale continues, supporting durable recovery potential.
Lower Leverage And Sizeable Asset BaseMaterial reduction in debt improves solvency and reduces interest burden, while a substantial asset base and remaining equity provide a buffer to fund R&D and manufacturing. Improved capital structure enhances financing optionality and lowers structural liquidity risk over the medium term.
Vertically Integrated CAR‑T And Manufacturing CapabilitiesOwning discovery, development and manufacturing creates a durable competitive edge in cell therapy: faster iteration, supply control, and potential margin capture on commercialization. Vertical integration reduces outsourcing risk and supports long-term scalability if clinical programs succeed.
Bears Say
Persistent Operating LossesLarge, ongoing operating losses indicate the business remains investment‑heavy and not yet self-sustaining. Continued negative earnings pressure equity and raise dependency on external funding; without durable margin improvement, losses can erode strategic flexibility and long‑term viability.
Deep Negative Operating Cash Flow And Weak FCFPersistent negative operating and free cash flows mean operations do not fund growth and R&D, forcing repeated financing. This reliance creates exposure to capital markets conditions, dilutive raises or higher borrowing costs, and limits ability to scale without external support.
Erosion Of Equity Base Over TimeSteady equity erosion reflects cumulative losses and reduces the company’s capital buffer. A smaller equity base constrains resilience to setbacks, increases the likelihood of dilutive financing, and reduces strategic optionality for long-term investments or M&A activity if losses persist.
CARsgen Therapeutics Holdings Ltd. News
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$10.87 and its highest was HK$28.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$8.59B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 55 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Mar 06, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.162 by HK$0.115.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.22.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 602,494,000 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.162. Following the earnings report the stock price went down -9.114%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$25.70 (72.60% Upside)
HK$25.70 (72.60% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.42%
12-Months-Change
Fundamentals
Return on Equity
-11.21%
Trailing 12-Months
Asset Growth
-19.17%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
2171 Stock 12 Month Forecast
Average Price Target
HK$25.70
▲(72.60% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
JW (Cayman) Therapeutics Co. Ltd.
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---